Moreover, the SYNGR2high group was more likely to gain benefits from anti-PD1/PDL1/PDL2 therapies in CESC, COAD, KICH, other tumor tissues, and respond to anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) therapy in BRCA, CESC, COAD, and other tumor tissues. The gene discussed is PDCD1; the disease is neoplasm.